Pfizer announced the sale of its 11.7% holding in ViiV Healthcare to a consortium led by Shionogi for $1.875 billion in cash. The transaction increases Shionogi’s stake to 21.7%, consolidating its position in the HIV therapeutics joint venture. Proceeds from the divestiture will be redeployed into Pfizer’s core growth initiatives, including late‐stage pipeline assets and strategic share repurchases, bolstering free cash flow by approximately $1.5 billion over the next 12 months and supporting an anticipated 8% increase in dividend distributions for 2026.

In its preliminary Q4 guidance, Pfizer highlighted continued mid‐single-digit volume growth for its anticoagulant franchise led by Eliquis, which generated nearly $10 billion in global sales through the first nine months of the year. Management forecasts a 6% to 8% year‐over-year revenue rise for non‐oncology products, offset by an expected 35% decline in COVID-19 vaccine and antiviral revenues due to lower booster uptake and fewer pandemic‐related hospitalizations. Key immunology and rare disease therapies, including Xeljanz and Vyndaqel, are projected to deliver stable mid‐teens percentage growth, underpinning overall segment resilience ahead of the full Q4 earnings release.

Pfizer was featured by HedgeFundTips editor Tom Hayes in MoneyShow’s annual list of best ideas for 2026, spotlighted for its diversified portfolio spanning vaccines, rare disease treatments and established growth drivers. Hayes cited Pfizer’s robust R&D pipeline—comprising eight phase III assets with peak sales potential exceeding $3 billion each—and its commitment to return at least $18 billion to shareholders through buybacks and dividends. The inclusion underscores Pfizer’s attractive risk-return profile for investors seeking a blend of defensive revenues and catalysts from late-stage clinical readouts scheduled over the next 12–18 months.